Classification of breast cancers into molecular subtypes may be important for the proper selection of therapy for patients as tumors with seemingly similar biology can have strikingly different clinical outcomes. The multi-center neo-adjuvant I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) showed that breast cancer subtypes as identified by immunohistochemistry or molecular analyses, have distinct clinical outcome1(Table 1 and 2). The median follow-up period of the trial is 3.9 years. Here, we present how the 70-gene signature (MammaPrint) now analyzed together with an 80-gene molecular subtyping profile2(BluePrint=Basal-type, Luminal-type, HER2-type) stratifies patients into molecular subgroups and show the relation to response to neo-adjuvant chemotherapy and survival for the I-SPY I patients.
Publication Name: Cancer Research, Poster